The agreement is a low-cost, non-dilutive way to generate early combination data in an indication with no approved second-line therapy. However, the study is exploratory, small-scale, and not registrational. Monitor for patient enrollment updates and any subsequent data readouts that could support a broader HPV-associated cancer strategy.
Drugs in focus
ONCY drug pipeline →pelareorep
◆ Mixed Named in this 8-K- Impact
- Phase
- Phase 2/3
- Time to market
- At least 3-5 years (Phase 3 just launching; no BLA/NDA filed)
- Next catalyst
- None dated
What to watchOncolytics is a single-asset clinical-stage biotech with no approved products. The stock trades at ~$0.92 against a mean analyst price target of ~$4.94 (~5x upside), but the company has limited cash (~$12.4M as of Q3 2025) and has tapped a $75M ATM facility, significant dilution risk. Watch for the Phase 3 pancreatic cancer trial launch (H1 2026) and any anal cancer registration updates, but do not expect a near-term binary catalyst.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Nov 12 $0.3720entry
- T+1 · 4d ago −0.54%α −0.17% · $0.3700
- T+2 · todayOpen
- T+5 · in 2d Pending
- T+20 · in 24d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
Oncolytics Biotech announced a clinical supply agreement with Coherus Oncology to evaluate its investigational oncolytic virus immunotherapy, pelareorep, in combination with Coherus' PD-1 inhibitor LOQTORZI (toripalimab-tpzi) in a Phase 2 study for second-line squamous cell anal carcinoma (SCAC). The study is expected to begin in Q1 2027 at a U.S. cancer center, with Coherus supplying LOQTORZI. No financial terms were disclosed, and the agreement does not provide near-term revenue or de-risk the development path.
Key Facts
- Oncolytics entered a clinical supply agreement with Coherus Oncology for a study of pelareorep + LOQTORZI in second-line SCAC patients.
- Study expected to begin in Q1 2027 at a premier U.S. cancer center.
- No approved therapy exists for second-line SCAC patients.
- Coherus will provide LOQTORZI; Oncolytics will partner with the sponsoring institution.
- No financial terms, milestone payments, or revenue commitments were disclosed.
- Pelareorep has Fast Track designation from the FDA for colorectal, anal, and pancreatic cancer.
Financial Impact
No financial terms disclosed; non-financial clinical supply agreement.
Risk Factors
- Study is early-stage and may not yield positive efficacy or safety data.
- No financial commitment from Coherus beyond drug supply; no milestone or royalty structure.
- Execution risk: enrollment timeline (Q1 2027) and site activation are uncertain.
- SCAC is a niche indication; commercial impact depends on expansion to broader HPV-associated cancers.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001129928-26-000082 |
| Document: oncolyticscoherusagmt.htm | 0001129928-26-000082 |
| Document: 0001129928-26-000082-index-headers.html | 0001129928-26-000082 |
| Document: 0001129928-26-000082-index.html | 0001129928-26-000082 |
| Document: 0001129928-26-000082.txt | 0001129928-26-000082 |
Track record
32 reports on ONCY
3 of 9 bullish or bearish reports moved the stock their way by T+20. Best: +10.53% at T+5 after the Apr 6, 2026 report. 7 of 12 went positive at some point.
Filters
- Nov 13, 20263d ago Press Release Neutral 3/10 Entry $0.3700 Now $0.3400 −8.11% settles Dec 14
- Nov 12, 20264d ago 8-K Neutral 3/10 Viewing Entry $0.3720 Now $0.3400 −8.60% settles Dec 11
- Nov 11, 20265d ago Press Release Neutral 3/10 Entry $0.3720 Now $0.3400 −8.60% settles Dec 11
- Nov 9, 20267d ago 8-K Neutral 3/10 Entry $0.4077 Now $0.3400 −16.61% settles Dec 8
- Nov 9, 20267d ago Press Release Neutral 3/10 Entry $0.4077 Now $0.3400 −16.61% settles Dec 8
- Nov 4, 202612d ago 8-K Neutral 4/10 Entry $0.4248 Now $0.3400 −19.96% settles Dec 3
- Nov 4, 202612d ago Press Release Bullish 6/10 Entry $0.4248 Now $0.3400 −19.96% settles Dec 3
- Oct 27, 202620d ago 8-K Bullish 6/10 Entry $0.4623 Now $0.3400 −26.45% settles Nov 24
- Oct 27, 202620d ago Press Release Bullish 6/10 Entry $0.4623 Now $0.3400 −26.45% settles Nov 24
- Oct 20, 202627d ago 8-K Neutral 3/10 Entry $0.4986 Now $0.3400 −31.81% settles Nov 17
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers